The drug is enriched with potent herbs and zinc and offers a supportive approach to assist patients during their recovery from COVID-19
The Ministry of Ayush, Government of India, recently approved CoroQuil-Zn, an herbal drug developed by Remedium Therapeutics in collaboration with Delhi Pharmaceutical Sciences and Research University, as an add-on treatment for mild and moderate COVID-19. The innovative herbal formulation, enriched with potent herbs and zinc, offers a supportive approach to assist patients during their recovery from COVID-19.
With the growing recognition of complementary therapies, CoroQuil-Zn offers a combination of traditional herbal knowledge and modern scientific advancements, designed to improve immunity and manage symptoms during COVID-19 recovery.
Developed by Remedium Therapeutics, in partnership with Delhi Pharmaceutical Sciences and Research University, CoroQuil-Zn focuses on enhancing the body’s natural immunity using a blend of herbs no with antioxidant, antiviral, and immunomodulatory properties, combined with zinc to boost the immune system. This combination aims to provide a natural, complementary option that works alongside other COVID-19 treatments.
Pat Krishnan, Founder and CEO, Remedium Therapeutics, highlighted the importance of CoroQuil-Zn in supporting respiratory health and said, “The pandemic has made it clear that respiratory health is paramount. We proudly introduce CoroQuil-Zn as a natural, effective add-on therapy that supports immunity, reduces inflammation, and promotes respiratory health. This herbal product combines traditional Ayurvedic knowledge with modern research to provide support for those battling COVID-19.”
